TDF partners help us customize and execute each project to its fullest. We partner with various organizations and resources to help shape and advance our projects to their desired endpoints.
TIDO invites inquiries for partnerships and collaborations. Interested parties can contact the Technology Development Fund at technology.development@childrens.harvard.edu.
Technology Development Fund Advisory Board
| Advisory Board Member | Title and Organization |
| Joe Bolen, PhD | Chief Scientific Officer, PureTech Health |
| Jerry Casey, MBA | Independent Consultant Former President and COO, Sekisui Diagnostics, LLC |
| Margaret Chu-Moyer, PhD | Executive Director of Researcha and Massachusetts Site Head, Amgen |
| Anthony J. Coyle, PhD | CEO, Pandion Therapeutics |
| Alan Crane, MBA | Venture Partner and Entrepreneur, Polaris Venture Partners |
| Skip Fleshman, MS | Partner, Asset Management Ventures |
| Sandra Glucksman, PhD | President and CEO, Cedilla Therapeutics |
| Keith Gottesdiener, MD | CEO, Rhythm Pharmaceuticals, Inc. |
| Michael Magliochetti, MBA, PhD | Operating Partner, Riverside Partners |
| Imran Nasrullah, MS, JD, CLP | Vice President, Head, Open Innovation Center, North America – East, Bayer |
| Simon Read, PhD | Chief Scientific Officer, Ra Pharma |
| Ken Rhodes, PhD | Chief Scientific Officer, Yumanity Therapeutics |
| Craig Sorensen, PhD | Independent Pharma Consultant Former Vice President, External Research and Innovation, Vertex Pharmaceuticals Inc. |
| Beverly Teicher, PhD | Chief, Molecular Pharmacology Branch, National Cancer Institute |
| Josh Tolkoff, MS Eng | Managing Director, Ironwood Capital Management; Accelerator Executive, CIMIT |
| Stacie Weninger, PhD | Executive Director, F-Prime Biomedical Research Initiative |
Technology Development Fund Industry Partners
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |